← Back to Clinical Trials
Recruiting NCT07185425

NCT07185425 Impact of the NeuroCuple Device on Pain Management After Cesarean Delivery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07185425
Status Recruiting
Phase
Sponsor Inova Health Care Services
Condition Pain
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2025-10-13
Primary Completion 2027-09

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
NeuroCupleSham

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 180 participants in total. It began in 2025-10-13 with a primary completion date of 2027-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This will be a single-center, sham-controlled, 3 arms, randomized (1:1:1) prospective study in females undergoing cesarean delivery to investigate the impact of NeuroCuple™ non-pharmacological analgesic device for management of postoperative pain. The investigators hypothesize that women treated with the Neurocuple device will experience less pain and consequently require less opioid pain medication after cesarean delivery compared to women who receive standard post-surgical medication.

Eligibility Criteria

Inclusion Criteria: * Female 18 years or older able to provide informed consent in English or Spanish * Scheduled for a planned or unplanned non-emergent cesarean delivery under neuraxial anesthesia * Intact skin surfaces around the operative skin incision area at the site of patch application * Pfannestiel skin incision Exclusion Criteria: * Active drug abuse * Chronic opioid user * Severe chronic pain * Psoriasis vulgaris or other skin conditions precluding safe device application * Subject is concurrently participating in another research study with an investigational drug or medical device that in the Investigator's opinion could impact subject safety or study results * Subject with reasons to maintain an epidural beyond operative room * Subject with complex surgery or subject who may need more than a cesarean surgery with possible tubal sterilization procedure * Subject is deemed not suitable for the study at the discretion of the principal Investigator

Contact & Investigator

Central Contact

Antonio Saad, MD

✉ antonio.saad@inova.org

📞 7037766040

Principal Investigator

Antonio Saad, MD

PRINCIPAL INVESTIGATOR

Inova Health Care Services

Frequently Asked Questions

Who can join the NCT07185425 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07185425 currently recruiting?

Yes, NCT07185425 is actively recruiting participants. Contact the research team at antonio.saad@inova.org for enrollment information.

Where is the NCT07185425 trial being conducted?

This trial is being conducted at Falls Church, United States.

Who is sponsoring the NCT07185425 clinical trial?

NCT07185425 is sponsored by Inova Health Care Services. The principal investigator is Antonio Saad, MD at Inova Health Care Services. The trial plans to enroll 180 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology